5-ethylidene-pyrimidine-2,4,6-trione | 13207-85-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-ethylidene-pyrimidine-2,4,6-trione
• 英文别名: 5-Ethylidene-1,3-diazinane-2,4,6-trione
• CAS: 13207-85-7
• 化学式: C₆H₆N₂O₃
• 分子量: 154.125
• InChiKey: YQGIYSQUUPDYDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  75.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] FUSED 1,3-AZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS FUSIONNÉS DE 1,3-AZOLE UTILES POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2016094688A1

  公开（公告）日：2016-06-16

  The present disclosure provides compounds of Formula (I-a), Formula (I), and Formula (II),. The compounds described herein may be Myc modulators (e.g., Myc inhibitors) and may be useful in treating in a subject in need thereof diseases associated with Myc and proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein. (Formulae (I-a), (I), (II))

  本公开提供了式(I-a)、式(I)和式(II)的化合物。本文描述的化合物可能是Myc调节剂（例如，Myc抑制剂），并且可能在治疗与Myc和增殖性疾病（例如癌症）相关的患者中有用。本公开还提供了包括本文描述的化合物的药物组合物、试剂盒、方法和用途。（式(I-a)、(I)、(II)）
• MYC MODULATORS AND USES THEREOF
  申请人：Massachusetts Institute of Technology

  公开号：US20160168165A1

  公开（公告）日：2016-06-16

  The present disclosure provides compounds of Formula (I-a), Formula (I), and Formula (II). The compounds described herein may be Myc modulators (e.g., Myc inhibitors) and may be useful in treating in a subject in need thereof diseases associated with Myc and proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.

  本公开提供式(I-a)、式(I)和式(II)的化合物。本文所描述的化合物可能是Myc调节剂（例如Myc抑制剂），并且可能有用于治疗与Myc和增殖性疾病（例如癌症）相关的患者。本公开还提供了包括所述化合物的药物组合物、试剂盒、方法和用途。
• COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT
  申请人：THE UNIVERSITY OF NEW ORLEANS

  公开号：US20160235752A1

  公开（公告）日：2016-08-18

  Embodiments of the present disclosure provide for compositions including an antimicrobial agent, pharmaceutical compositions including the antimicrobial agent, methods of treatment of an infection, methods of treatment using compositions or pharmaceutical compositions, and the like.

  本公开的实施例提供了包括抗微生物剂的组合物、包括抗微生物剂的药物组合物、治疗感染的方法、使用组合物或药物组合物的治疗方法等。
• ULTRAVIOLET ABSORBER COMPOSITION
  申请人：Fujifilm Corporation

  公开号：EP2116585A1

  公开（公告）日：2009-11-11

  An ultraviolet absorbent composition, containing: at least one kind of ultraviolet absorbent A having an absorption maximum wavelength of from 350 nm to 400 nm, a half value width of 55 nm or less and a molar extinction coefficient of 20,000 or more at the absorption maximum wavelength; and at least one kind of ultraviolet absorbent B having an absorption maximum wavelength of 350 nm or less and showing 30% or more of absorbance at 320 nm of the absorbance at the absorption maximum wavelength.

  一种紫外线吸收剂组合物，含有 至少一种紫外线吸收剂 A，其最大吸收波长为 350 纳米至 400 纳米，半值宽度为 55 纳米或以下，在最大吸收波长处的摩尔消光系数为 20,000 或以上；以及 至少一种紫外线吸收剂 B，其最大吸收波长为 350 纳米或以下，在 320 纳米处的吸收率为最大吸收波长处吸收率的 30%或以上。
• Histone deacetylase inhibitors
  申请人：Karus Therapeutics Limited

  公开号：US10870624B2

  公开（公告）日：2020-12-22

  The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors.

  本发明是一种式化合物或其药学上可接受的盐。这些化合物可用作 HDAC 抑制剂。